The Technical Analyst
Amicus Therapeutics Inc [FOLD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Amicus Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.09% $10.33
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 051.31 mill |
| EPS: | -0.510 |
| P/E: | -20.25 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 295.38 mill |
| Avg Daily Volume: | 3.04 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -20.25 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.44x |
| Company: PE -20.25 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.88 - 10.80 ( +/- 4.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Prout Samantha | Sell | 7 027 | Common Stock |
| 2024-04-01 | Campbell Bradley L | Buy | 7 500 | Common Stock |
| 2024-04-01 | Campbell Bradley L | Sell | 7 500 | Common Stock |
| 2024-04-01 | Campbell Bradley L | Sell | 7 500 | Stock Options (right to buy) |
| 2024-03-15 | Campbell Bradley L | Sell | 13 375 | Common Stock |
| INSIDER POWER |
|---|
| 17.41 |
| Last 100 transactions |
| Buy: 1 738 926 | Sell: 1 191 633 |
Forecast:
16:00 - $10.34
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $10.34
Forecast 2: 16:00 - $10.34
Forecast 3: 16:00 - $10.34
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.33 (-2.09% ) |
| Volume | 1.645 mill |
| Avg. Vol. | 3.04 mill |
| % of Avg. Vol | 54.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FOLD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $13.31 | N/A | Active |
|---|
FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Last 10 Buy Signals
Latest Press Releases
2024-03-20 07:00:00 - Press Release
Amicus Therapeutics Issues 2024 Environmental, Social, And Governance (esg) Report
Princeton, n.j., march 20, 2024 (globe newswire) -- amicus therapeutics (nasdaq: fold), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual environmental, social, and governance (esg) report. this year's report highlights the strength of the company's corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensuring broad and equitable access to our innovative therapies, fostering an inclusive culture to ensure equal representation and participation for all, and maintaining our leadership of strong business ethics and integrity.
2024-03-01 07:00:00 - Press Release
Amicus Therapeutics To Present At Upcoming Investor Conferences In March 2024
Princeton, n.j., march 01, 2024 (globe newswire) -- amicus therapeutics (nasdaq: fold) today announced that management will participate in upcoming presentations at the following investor conferences in march.
2024-02-28 07:00:00 - Press Release
Amicus Therapeutics Announces Full-year 2023 Financial Results And Corporate Updates
2023 total revenue of $399.4m, a 21% increase year-over-year strong patient demand continues for pombiliti ™ + opfolda ™ in the u.s., u.k., and germany projecting 2024 galafold ® revenue growth of 11-16% at cer anticipating full-year non-gaap profitability in 2024 conference call and webcast today at 8:30 a.m. et princeton, n.j.
2024-02-15 07:00:00 - Press Release
Amicus Therapeutics To Announce Full Year 2023 Financial Results On February 28, 2024
Princeton, n.j., feb. 15, 2024 (globe newswire) -- amicus therapeutics (nasdaq: fold) today announced that the company will host a conference call and live audio webcast on wednesday, february 28, 2024, at 8:30 a.m. et to discuss financial results for the full-year ended december 31, 2023.
2024-02-08 07:00:00 - Press Release
Amicus Therapeutics Receives The 2024 New Treatment Award For Pombiliti™ (cipaglucosidase Alfa-atga) + Opfolda™ (miglustat) At The 20th Annual Worldsymposium™
- award recognizes approval of amicus therapeutics' two-component therapy for the treatment of late-onset pompe disease - - award recognizes approval of amicus therapeutics' two-component therapy for the treatment of late-onset pompe disease -
Latest News
2024-03-29 12:36:22 - Zacks Investment Research
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
2024-03-01 07:00:00 - GlobeNewsWire
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
2024-02-29 12:26:06 - Zacks Investment Research
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
2024-02-29 10:05:48 - Seeking Alpha
Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Amicus Therapeutics should deliver strong topline growth with expanding margins and increasing cash flows in 2024.
2024-02-28 09:20:20 - Zacks Investment Research
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.19 per share a year ago.
2024-02-15 07:00:00 - GlobeNewsWire
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023.
2024-01-16 09:00:28 - MarketBeat
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Companies can usually gauge if their previous forecasts were in line or need to be adjusted to warn or prepare investors ahead of time.
2024-01-08 11:23:51 - Zacks Investment Research
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
2023-12-29 11:16:46 - Zacks Investment Research
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential.
2023-11-09 14:17:21 - Zacks Investment Research
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated
Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates.